US Biopharm Services Firm Parexel Acquires Taiwanese CRO for US$51 Million (Taiwan)
This article was originally published in PharmAsia News
U.S.-based contract research organization Parexel International Corp. announced its buyout of Taiwan's Apex International Clinical Research Co. on Sept. 26. Parexel bought the firm, which will now operate as Parexel Apex International, for $50.9 million. Parexel hopes its partnership with Apex will help it to access Asia's growing healthcare and pharmaceutical markets. Apex already supplies the regional medical industry with a number of services including consultations, clinical monitoring, data management, and site management. Asides from its Taiwan headquarters, which has about 350 employees, Apex has several other locations around the region, including China, Hong Kong, Korea, India, Singapore, the Philippines, Malaysian, Indonesia, Thailand, Australia, and New Zealand. Apex's Taiwan location is especially advantageous in light of the fact that as of June 6, 2007, Taiwan had more clinical trials than anywhere else in the area with 532 active trials. Japan came in second with 328, China had 275, and Indian 270. (Click here for more - May Require Free Registration
You may also be interested in...
With local variations, Asian countries are accepting Phase III data from multinational studies that include patients from their country – even if they live in Los Angeles.
PERTH, Australia - Global studies that include Asia should be part of any multinational company's strategy to accelerate development time and gain access to the Asian market, a Parexel exec told the recent BioMedical Asia conference in Singapore
In final rule describing the types of evidence the agency will consider in determining the ‘intended use’ of a product, FDA rejects industry requests to exclude ‘circumstances surrounding distribution’ and product design or composition.